Sept. 8 Quick Takes: Logos leads crossovers in Attralus’ $116M round

A Logos Capital-led $116 million series B round for Attralus Inc. brings on board a robust syndicate of crossovers and adds Sarissa Capital Management’s Alex Denner and former Myokardia Inc. CBO Jake Bauer to the company’s board. In addition to Logos and Sarissa, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Citadel’s Surveyor Capital, Vivo Capital and founding investor venBio Partners participated in the financing, which will advance the company’s pan-amyloid removal (PAR) therapeutics toward the clinic for systemic amyloidosis.

Launched in 2020 with $800 million in venture funds, National Resilience Inc. announced Wednesday it will manufacture mRNA to support worldwide distribution of SpikeVax from Moderna Inc. (NASDAQ:MRNA). Production will take place at Resilience’s 136,000-square-foot plant in Ontario, which the Arch Venture Partners-built manufacturing company acquired in March; in May, the Government of Canada invested CAD 199.2 million ($163.8 million) in the company's Ontario-based subsidiary Resilience Biotechnologies Inc. to modernize and expand production capacity at the facility. Resilience did not disclose how many SpikeVax doses it plans to produce...